Comparative immunology, implication for vaccine discovery

Le développement des vaccins pour l’homme comprend des exigences particulières. Il s’agit, en effet, de l’un des rares produits pharmaceutiques injectés à des individus en bonne santé dont le bénéfice attendu est à moyen ou long terme. Par ailleurs, la mesure de l’efficacité au sein d’une population exposée aux maladies infectieuses, qu’il s’agisse d’endémies, d’épidémies récurrentes ou d’émergences, est complexe, notamment du fait des contraintes sociétales, méthodologiques et statistiques. Pour l’ensemble de ces raisons, la recherche sur les vaccins fait une part importante aux études chez l’animal, en particulier les primates non-humains, en raison de leur proximité phylogénique avec l’homme. Les nouvelles technologies permettent l’exploration de la réponse immune dans ces espèces et la visualisation, chez l’individu vivant par des approches peu invasives, des interactions du pathogène avec l’hôte. Ils représentent des atouts importants pour le développement des vaccins du futur tout en préservation le bien-être des animaux en recherche biomédicale.The development of human vaccines have several specificities. Vaccines are one of the rare pharmaceutical product injected to healthy people with an expected benefit in the mid and long-term. In addition, the evaluation of vaccine efficacy in populations exposed to infectious diseases, including endemics, recurrent epidemics and emerging diseases, is complex, in particular due to social, methodological and statistical constraints. Therefore, research of human vaccines include a large part of animal studies, and the non-human primates in particular due to their close phylogenetic proximity with humans. The new advanced technologies for immunology and for the visualization of host-pathogen interaction in vivo with little invasive approaches, offer new opportunities for vaccine development while taking into account the welfare of animals in biomedical research

Rôle des leucocytes infectés du sperme dans la transmission muqueuse du VIH (Modèle expérimental de l infection par le SIVmac251 de Macaca fascicularis)

Aujourd hui, plus de 80% des nouvelles infections par le virus de l immunodéficience humaine (VIH) se produisent au cours d un rapport sexuel, avec une transmission du virus par voie muqueuse. Le sperme constitue donc une source majeure de virus à l échelle mondiale. Le sperme d hommes infectés par le VIH contient le virus sous deux formes : des particules virales libres et des cellules infectées, principalement des leucocytes.Plusieurs hypothèses ont été proposées afin d expliquer le passage du virus à travers la barrière muqueuse, qu il s agisse d une muqueuse génitale (cervico-vaginale, pénienne ou urétrale) ou intestinale (muqueuse anale ou rectale). Toutefois, une grande majorité des études qui ont été menées jusqu à présent se sont concentrées sur le rôle des particules virales libres, et celui des cellules infectées demeure mal compris. Une étude menée dans notre laboratoire a montré que des leucocytes infectés par le virus de l immunodéficience simienne (VIS) sont capables de transmettre l infection après inoculation vaginale.Le projet de cette thèse est d étudier le rôle des leucocytes infectés présents dans le sperme de macaque dans la transmission muqueuse du VIS/VIH. Ainsi, trois axes d étude principaux ont été définis: 1) l étude des leucocytes présents dans le sperme de macaque cynomolgus, et de l influence que peut avoir l infection par le VIS sur eux ; 2) l identification des cellules immunitaires infectées présentes dans le sperme de macaque, et l étude de leur dynamique au cours de l infection par le VIS. ; 3) l étude du pouvoir infectieux des deux principales cellules cibles pour le VIS/VIH : les lymphocytes CD4+ (LT CD4+) et les macrophages, in vitro et in vivo, après inoculation rectale et vaginale à des macaques cynomolgus.Le sperme de macaque contient toutes les cellules cibles du VIS/VIH : des lymphocytes T CD4+ (LTCD4+), des macrophages et des cellules dendritiques dans une moindre proportion). Les LTCD4+ et les macrophages du sperme présentent un phénotype d activation, de différenciation et d expression de marqueurs de migration typique des leucocytes résidant dans les tissus muqueux. L infection par le VIS induit des changements significatifs dans leur phénotype et leur dynamique. Ces deux types cellulaires peuvent être infectés de façon productive et sont présents dans le sperme à tous les stades de l infection. Ces données suggèrent que les LTCD4+ et les macrophages du sperme seraient capables de transmettre l infection par voie muqueuse.Si le rôle des leucocytes infectés du sperme est confirmé in vivo, il sera important à l avenir de prendre en compte ce mécanisme de transmission dans le développement de nouvelles stratégies préventives de l infection par le VIH, notamment les microbicides.Human Immunodeficiency Virus (HIV) infection mostly spreads by the mucosal route: sexual transmission is the dominant mode of transmission, responsible for between 85% and 90% of cases of infection worldwide. These epidemiological data indicate that semen is one of the major sources of HIV-1 transmission. Semen, like other bodily secretions involved in HIV sexual transmission, contains the virus as two forms: cell-free viral particles and cell-associated virus, mostly in infected leukocytes. Although cell-to-cell HIV transmission has been extensively described as more efficient, rapid and resistant to host immune responses, very few studies have investigated the role in vivo of infected leukocytes in virus mucosal transmission. One such study has been recently conducted in our lab, and demonstrated that SIV-infected splenocytes are able to transmit infection to female macaques after vaginal exposure. However, all these studies used immune cells from peripheral blood or lymphoid tissues, such as spleen, and none have investigated the capacity of infected leukocytes in semen to transmit the infection in vivo. Indeed, nature, phenotype and infectivity of HIV associated with semen leukocytes may be different from that of HIV from other sources.Therefore, the objectives of this work are, first, to study of semen leukocytes and their dynamics during SIVmac251 infection in detail, then to investigate seminal factors that may influence semen infectiousness, and finally to test semen leukocyte infectivity in vitro and in vivo, using a model of mucosal exposure in cynomolgus macaques.Macaque semen contains all the target cells for HIV/SIV: CD4+ T cells, macrophages and dendritic cells in lower proportions. Semen CD4+ T cells and macrophages display an activation, differenciation and expression of migration markers profile which is typical of mucosal leucocytes. SIV infection induces significant changes in their phenotype and dynamics. Both cell types can be productively infected and are found in the semen at all stages of infection. These observations suggest that semen CD4+ T cells and macrophages may be able to transmit infection after mucosal exposure.If the role of semen infected leukocytes in HIV/SIV mucosal transmission is confirmed in vivo, this mechanism will be important to consider for further preventive strategies design, like microbicides.PARIS11-SCD-Bib. électronique (914719901) / SudocSudocFranceF

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

International audienceNo abstract availabl

Towards a vaccine against AIDS

International audiencen.

Impact of short term HAART initiated during the acute or chronic stage on SIV infection of the male genital tract

International audiencen.

Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals

Viral vectors are increasingly used as delivery means to induce a specific immunity in humans and animals. However, they also impact the immune system, and it depends on the given context whether this is beneficial or not. The attenuated vaccinia virus strain modified vaccinia virus Ankara (MVA) has been used as a viral vector in clinical studies intended to treat and prevent cancer and infectious diseases. The adjuvant property of MVA is thought to be due to its capability to stimulate innate immunity. Here, we confirmed that MVA induces interleukin-8 (IL-8), and this chemokine was upregulated significantly more in monocytes and HLA-DR(bright)dendritic cells (DCs) of HIV-infected patients on combined antiretroviral therapy (ART) than in cells of healthy persons. The effect of MVA on cell surface receptors is mostly unknown. Using mass cytometry profiling, we investigated the expression of 17 cell surface receptors in leukocytes afterex vivoinfection of human whole-blood samples with MVA. We found that MVA downregulates most of the characteristic cell surface markers in particular types of leukocytes. In contrast, C-X-C motif chemokine receptor 4 (CXCR4) was significantly upregulated in each leukocyte type of healthy persons. Additionally, we detected a relative higher cell surface expression of the HIV-1 co-receptors C-C motif chemokine receptor 5 (CCR5) and CXCR4 in leukocytes of HIV-ART patients than in healthy persons. Importantly, we showed that MVA infection significantly downregulated CCR5 in CD4+ T cells, CD8+ T cells, B cells, and three different DC populations. CD86, a costimulatory molecule for T cells, was significantly upregulated in HLA-(DRDCs)-D-bright after MVA infection of whole blood from HIV-ART patients. However, MVA was unable to downregulate cell surface expression of CD11b and CD32 in monocytes and neutrophils of HIV-ART patients to the same extent as in monocytes and neutrophils of healthy persons. In summary, MVA modulates the expression of many different kinds of cell surface receptors in leukocytes, which can vary in cells originating from persons previously infected with other pathogens

Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion

<p>Abstract</p> <p>Background</p> <p>HIV reservoirs are rapidly established after infection, and the effect of HAART initiated very early during acute infection on HIV reservoirs remains poorly documented, particularly in tissue known to actively replicate the virus. In this context, we used the model of experimental infection of macaques with pathogenic SIV to assess in different tissues: (i) the effect of a short term HAART initiated at different stages during acute infection on viral dissemination and replication, and (ii) the local concentration of antiviral drugs.</p> <p>Results</p> <p>Here, we show that early treatment with AZT/3TC/IDV initiated either within 4 hours after intravenous infection of macaques with SIVmac251 (as a post exposure prophylaxis) or before viremia peak (7 days post-infection [pi]), had a strong impact on SIV production and dissemination in all tissues but did not prevent infection. When treatment was initiated after the viremia peak (14 days pi) or during early chronic infection (150 days pi), significant viral replication persists in the peripheral lymph nodes and the spleen of treated macaques despite a strong effect of treatment on viremia and gut associated lymphoid tissues. In these animals, the level of virus persistence in tissues was inversely correlated with local concentrations of 3TC: high concentrations of 3TC were measured in the gut whereas low concentrations were observed in the secondary lymphoid tissues. IDV, like 3TC, showed much higher concentration in the colon than in the spleen. AZT concentration was below the quantification threshold in all tissues studied.</p> <p>Conclusions</p> <p>Our results suggest that limited antiviral drug diffusion in secondary lymphoid tissues may allow persistent viral replication in these tissues and could represent an obstacle to HIV prevention and eradication.</p

Impact of Short-Term HAART Initiated during the Chronic Stage or Shortly Post-Exposure on SIV Infection of Male Genital Organs

International audienceBACKGROUND: The male genital tract is suspected to constitute a viral sanctuary as persistent HIV shedding is found in the semen of a subset of HIV-infected men receiving effective antiretroviral therapy (HAART). The origin of this persistent shedding is currently unknown. Phylogenetic studies indicated that HIV in semen from untreated men arises from local sources and/or passive diffusion from the blood. We previously demonstrated in human and macaque low levels and localized infection of several semen-producing organs by HIV/SIV. Using a macaque model, this study investigates the impact of short term HAART (2-4 weeks) initiated either during the asymptomatic chronic stage or 4 h post-intravenous inoculation of SIVmac251 on the infection of male genital organs. METHODOLOGY/PRINCIPAL FINDINGS: Short term HAART during the chronic stage decreased blood viral load. No major impact of HAART was observed on SIV DNA levels in male genital organs using a sensitive nested PCR assay. Using in situ hybridization, SIV RNA+ cells were detected in all male genital tract organs from untreated and treated animals with undetectable blood viral load following HAART. Infected CD68+ myeloid cells and CD3+ T lymphocytes were detected pre- and post-HAART. In contrast, short term HAART initiated 4 h post-SIV exposure led to a drastic decrease of the male genital tissues infection, although it failed to prevent systemic infection. In both cases, HAART tended to decrease the number of CD3+ T cells in the male organs. CONCLUSIONS: Our results indicate that the established infection of male genital organs is not greatly impacted by short term HAART, whereas the same treatment during pre-acute phase of the infection efficiently impairs viral dissemination to the male genital tract. Further investigations are now needed to determine whether infection of male genital organs is responsible for long term persistent HIV shedding in semen despite HAART

Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251

BACKGROUND: The aim of this study was to evaluate gene therapy for AIDS based on the transduction of circulating lymphocytes with a retroviral vector giving low levels of constitutive macaque interferon β production in macaques chronically infected with a pathogenic isolate of SIVmac251. RESULTS: Two groups of three animals infected for more than one year with a pathogenic primary isolate of SIVmac251 were included in this study. The macaques received three infusions of their own lymphocytes transduced ex vivo with the construct encoding macaque IFN-β (MaIFN-β or with a vector carrying a version of the MaIFN-β gene with a deletion preventing translation of the mRNA. Cellular or plasma viremia increased transiently following injection in most cases, regardless of the retroviral construct used. Transduced cells were detected only transiently after each infusion, among the peripheral blood mononuclear cells of all the animals, with copy numbers of 10 to 1000 per 10(6 )peripheral mononuclear cells. CONCLUSION: Long-term follow-up indicated that the transitory presence of such a small number of cells producing such small amounts of MaIFN-β did not prevent animals from the progressive decrease in CD4(+ )cell count typical of infection with simian immunodeficiency virus. These results reveal potential pitfalls for future developments of gene therapy strategies of HIV infection